Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

70.41 +0.46 (+0.66%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,955,495
Open 69.96
Bid (Size) 70.25 (2)
Ask (Size) 70.84 (7)
Prev. Close 69.95
Today's Range 69.91 - 70.59
52wk Range 61.24 - 87.67
Shares Outstanding N/A
Dividend Yield 2.98%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AstraZeneca’s record seventh year of plenary data at ASCO furthers ambition to redefine breast cancer care and transform outcomes in gastric cancer
From AstraZeneca
Via Business Wire
3 Promising Growth Stocks You Can Buy for Less Than $100
Via The Motley Fool

Performance

YTD
+6.9%
+6.9%
1 Month
+3.7%
+3.7%
3 Month
-5.6%
-5.6%
6 Month
+9.6%
+9.6%
1 Year
-10.6%
-10.6%

More News

Read More
How Does D-Wave Stack Up Against Quantum Competitors?
Via MarketBeat
Statistically significant and clinically meaningful BATURA Phase III trial results provide new evidence for AIRSUPRA as standard of care for as-needed rescue treatment in asthma
From AstraZeneca
Via Business Wire
What Does the Market Think About AstraZeneca?
Via Benzinga
George Soros Loads Up On First Solar Calls: What Does He Know That Wall Street Doesn't?
Via Benzinga
Novo Nordisk Sheds 4% After Ousting CEO As Eli Lilly Rivalry Slams Stock Price
Via Investor's Business Daily
Exposures Product Safety
Merck Data Shows Positive Outcomes For Ovarian Cancer Patients Treated With Keytruda
Via Benzinga
P/E Ratio Insights for AstraZeneca
Via Benzinga
AstraZeneca to showcase latest research on comprehensive portfolio and pipeline aimed at transforming respiratory diseases at ATS 2025
From AstraZeneca
Via Business Wire
Trump’s ‘Most Favored Nation’ Drug Plan Likely To Face Pushback, JP Morgan Analysts Say
Via Stocktwits
Topics ETFs Government Stocks
Exposures Political US Equities
AstraZeneca Reports Positive Data From Cancer Drug Trial: Retail Sentiment Brightens
Via Stocktwits
IMFINZI® (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial
From AstraZeneca
Via Business Wire
Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks
Via Benzinga
Topics ETFs Government
Exposures Political
Tempus AI Stock: Time to Double Down or Cut and Run?
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11
From AstraZeneca
Via Business Wire
Tempus AI Strikes $200M Deal With AstraZeneca, Pathos To Build World's Largest Oncology Model
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
AstraZeneca Gets Approval For Oncology Drug To Treat Mantle Cell Lymphoma In EU: But Retail Sentiment Dips
Via Stocktwits
AstraZeneca's Triple-Combination Therapy Breztri Hits Primary Goals In Two Pivotal Studies For Asthma
Via Benzinga
Think It's Too Late to Buy Tempus AI? Here's the Biggest Reason Why There's Still Time.
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
AstraZeneca’s Breztri Therapy Meets Primary Goals In Late-Stage Trials To Treat Asthma: Retail’s Positive
Via Stocktwits
BREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma
From AstraZeneca
Via Business Wire
AstraZeneca Q1 Earnings Rise, But China Drug Allegations May Lead To $8 Million Penalty
Via Benzinga
AstraZeneca Beat Earnings Views, But Sales Come In Light As Cancer Study Flops
Via Investor's Business Daily
Topics Earnings Government
Exposures Financial Political Product Safety
NXP Semiconductors, Brinker International, Ultra Clean, Sanmina And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga

Frequently Asked Questions

Is AstraZeneca PLC - American Depositary Shares publicly traded?
Yes, AstraZeneca PLC - American Depositary Shares is publicly traded.
What exchange does AstraZeneca PLC - American Depositary Shares trade on?
AstraZeneca PLC - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for AstraZeneca PLC - American Depositary Shares?
The ticker symbol for AstraZeneca PLC - American Depositary Shares is AZN on the Nasdaq Stock Market
What is the current price of AstraZeneca PLC - American Depositary Shares?
The current price of AstraZeneca PLC - American Depositary Shares is 70.41
When was AstraZeneca PLC - American Depositary Shares last traded?
The last trade of AstraZeneca PLC - American Depositary Shares was at 05/23/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.